WhatsApp
backNews Article

Gland Pharma Releases Unaudited Q2 and Half Year FY27 Financial Results

Board approved results for period ending September 30, 2026, reviewed by Deloitte Haskins & Sells and posted on official platforms

Gland Pharma Limited announced its unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2026. The results were approved by the Board on November 6, 2026, accompanied by limited review reports from Deloitte Haskins & Sells. Detailed results are available on the company's website and the stock exchanges' portals.

07 Nov 2026|GLAND+0.35%
Gland Pharma Limited543245GLANDGeneral / Other

Gland Pharma Limited

General / Other

Gland Pharma Limited has announced its unaudited consolidated and standalone financial results for the quarter and half year ending September 30, 2026, following approval by its Board of Directors on November 6, 2026.

The unaudited financial results were subjected to limited review by the company's statutory auditors, Deloitte Haskins & Sells.

These results are accessible to investors and the public on Gland Pharma’s official website as well as on the BSE and NSE stock exchange websites.

The announcement complies with Regulation 33 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency and timely dissemination of financial information.

No specific profit or loss figures were disclosed in the announcement; it serves primarily to notify availability and approval of the financial statements for the referenced reporting period.

Highlights

  • Unaudited financial results for Q2 and H1 FY27 approved on November 6, 2026.
  • Consolidated and standalone results reviewed by Deloitte Haskins & Sells.
  • Results published on company and stock exchange websites for investor access.
  • Compliance with SEBI regulations 33 and 47 for disclosure and publication.

Key Data Snapshot

Reporting periodQuarter and half year ended September 30, 2026
Board approval dateNovember 6, 2026
AuditorDeloitte Haskins & Sells
Regulatory complianceSEBI Listing Obligations and Disclosure Requirements Regulations, 2015
Stock exchange tickers543245 (BSE), GLAND (NSE)

What happened

  • Gland Pharma’s Board approved the unaudited financial results for Q2 and half year ended September 30, 2026.
  • The results include both consolidated and standalone financial statements.

Key details

  • Limited review reports were obtained from the statutory auditors, Deloitte Haskins & Sells.
  • Results are published on the company website and on BSE and NSE platforms.
  • Announcement fulfills SEBI regulatory requirements for financial disclosures.

Regulatory and governance context

  • Compliance with Regulation 33 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  • Ensures timely dissemination of unaudited financial results to stakeholders.

More News on General / Other

View all

Latest corporate announcements and market updates in General / Other.

View all news
Gland Pharma Releases Unaudited Q2 and Half Year FY27 | Stockk News